79% of Patients Achieve Normal Liver Fat at Week 24 with CIDEBsiRNA
Following a single subcutaneous dose of Regeneron Pharmaceuticals, Inc.’s investigational RNA interference therapy CIDEBsiRNA, a substantial proportion of trial participants with metabolic dysfunction-associated steatotic liver disease achieved normal liver fat levels by week 12. Metabolic dysfunction-associated steatotic liver disease affects approximately 33 percent of adults worldwide, yet effective treatment options remain limited for patients who … Read more